News for Pulmatrix, Inc. (PULM)

Pulmatrix (PULM) has resumed trading, drawing attention from investors eager to monitor its performance. The company recently halted activity, but now the marke

At 11:37 EDT, trading for Pulmatrix (PULM) was temporarily suspended as a result of a volatility trading pause. Such pauses are typically implemented to stabili

PR NewswireFRAMINGHAM, Mass., May 15, 2025 Registration statement for proposed Cullgen merger declared effective by the SEC Proposed merger anticipated to

Pulmatrix (PULM) reports zero revenue and a net loss of $1.8M in Q1 2025. The company is set to divest key assets before merging with Cullgen in June 20

Pulmatrix (PULM) reports Q1 GAAP EPS of -$0.50. Stay updated on Pulmatrix's financial performance and market position.

PR NewswireNEW YORK, May 13, 2025 NEW YORK, May 13, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp

Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q ...

PR NewswireFRAMINGHAM, Mass., March 21, 2025 Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025As part of

PR NewswireNEW YORK, Feb. 25, 2025 NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

**media[521462]**

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed

PR NewswireNEW YORK, Nov. 21, 2024 NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11%

Pulmatrix announces merger agreement with Cullgen, creating new biopharmaceutical company headquartered in San Diego, CA and trading on Nasdaq.

Elicio Therapeutics announces new CFO and accounting officer

Pulmatrix reports progress in migraine treatment study

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Consumer discretionary major Titan Co saw 22% revenue growth for the third quarter ended December. The growth was broad-based as most of the segments put up a healthy performance during the quarter.